Main navigation

"Complete Fraud": Citron Research Founder Lambasts Crypto

Advertisement
Mon, 11/07/2022 - 19:59
"Complete Fraud": Citron Research Founder Lambasts Crypto
Cover image via stock.adobe.com
Read U.TODAY on
Google News

Citron Research's Andrew Left had some not-so-nice things to say about cryptocurrencies, Reuters reports.

The famed short-seller went as far as calling cryptocurrencies “complete fraud.”

It is not clear whether Left himself holds any digital assets, but his assessment suggests that he’s far from being a crypto enthusiast.

Back in 2017, the investor criticized Grayscale’s Bitcoin Trust, claiming that its valuation was “ridiculous.” He claimed that the leading crypto money manager didn’t even have insurance for its Bitcoin.

In November 2020, Cintron Research said that it was long Bitcoin because there was no better inflation hedge in the market. It appears that the company no longer holds such a view.

Related
The firm stated that it had a position in Michael Saylor’s MicroStrategy, claiming that owning the company’s stock was the best way to get exposure to Bitcoin.

Left gained prominence because of his attempts to expose fraud at major companies. In 2015, it successfully bet against Valeant Pharmaceuticals, the world's biggest drug company. Citron Research uncovered that the company was using specialty pharmacies in order to inflate its revenue. The stock of Valeant Pharmaceuticals collapsed while its longtime CEO resigned shortly after the scandal.    

In early 2021, Citron got caught up in the GameStop saga after shorting the stock of the controversial video game company and attracting the ire of retail investors and attracted the ire of disgruntled retail investors.

After facing relentless attacks from stock traders, Left said that he would stop publishing short-seller reports last year.

Related articles

Advertisement
TopCryptoNewsinYourMailbox
TopCryptoNewsinYourMailbox
Advertisement
Advertisement

Recommended articles

Latest Press Releases

Our social media
There's a lot to see there, too

Popular articles

Advertisement
AD